Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569853 · ClinicalTrials.gov registry record · Phase 3
DFN-11 Injection in Episodic Migraine With or Without Aura
A Phase 3 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
NCT02569853: Completed Phase 3 study, sponsored by Dr. Reddy's Laboratories Limited.
NCT02569853 is a Phase 3 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 268 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02569853, a Phase 3 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
Study Summary
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
Interventions
- OTHER Placebo
- DRUG DFN-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2015-09-21 |
| Est. Completion | 2018-02-26 |
| Phase | Phase 3 |
What the finished NCT02569853 record still lists
NCT02569853 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02569853 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02569853 about?
NCT02569853 is a clinical study titled "DFN-11 Injection in Episodic Migraine With or Without Aura". Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
What is the current status of trial NCT02569853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 2015-09-21. Estimated completion is 2018-02-26.
What interventions are being tested in trial NCT02569853?
The interventions under investigation include: Placebo (OTHER), DFN-11 (DRUG).
Who is sponsoring clinical trial NCT02569853?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02569853's enrollment target sits among peer trials
268 1222nd of 2000 higher than 779 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI